Publication date: Sep 03, 2019
Monthly injections of ofatumumab led to more clinically meaningful reductions in relapse rates and delayed disability progression than did daily treatment with Aubagio (teriflunomide) tablets in people with relapsing forms of multiple sclerosis (MS), results from two Phase 3 trials showed. -Ofatumumab, if approved, could be a highly attractive treatment option for a broad [relapsing MS] patient population, including early MS,” John Tsai, Novartis’s head global drug development and chief medical officer, said in a press release. The trials also showed that, at six months of treatment, patients give ofatumumab had fewer brain areas affected by active inflammation and disease activity, as well as fewer new or enlarging brain lesions, lesser brain volume loss, and lower blood levels of neurofilament light chain – a proposed MS biomarker. Published results of the Phase 2 MIRROR study (NCT01457924) also showed a marked reduction in new brain lesions over 48 weeks of treatment with ofatumumab compared to placebo. -This data signifies a possible turning point for ofatumumab and provides support for our belief that it has the potential, if approved, to become the first subcutaneous B-cell therapy for relapsing MS that can be self-administered by patients at home,” Jan van de Winkel, PhD, Genmab’s CEO, said in a separate press release.
|disease||DOID||chronic lymphocytic leukemia|
|drug||DRUGBANK||Antithymocyte immunoglobulin (rabbit)|
- Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies
- Novartis’ repurposed cancer drug Arzerra outpaces Sanofi’s Aubagio in multiple sclerosis trial
- Gilenya, Aubagio, Tysabri, Tecfidera Dominate MS Therapy Switches in Europe, Spherix Survey Finds
- Mavenclad Cost-Effective Treatment for At-risk RRMS Patients Compared to Other DMTs, Dutch Study Finds